Scarica l'app Stockscreener
24.26
3.37%
0.79
Precedente Chiudi:
$23.47
Aprire:
$23.29
Volume 24 ore:
496.27K
Relative Volume:
0.59
Capitalizzazione di mercato:
$1.88B
Reddito:
$688.00K
Utile/perdita netta:
$-170.19M
Rapporto P/E:
-7.9554
EPS:
-3.0495
Flusso di cassa netto:
$-154.68M
1 W Prestazione:
+3.23%
1M Prestazione:
+4.34%
6M Prestazione:
+64.14%
1 anno Prestazione:
-10.15%
Intervallo 1D:
$23.01
$24.97
Intervallo di 1 settimana:
$23.01
$25.42
Portata 52W:
$10.91
$29.06
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Nome
Spyre Therapeutics Inc
Settore
Industria
Telefono
(617) 651-5940
Indirizzo
221 CRESCENT STREET, WALTHAM
Confronta SYRE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
24.26 | 1.82B | 688.00K | -170.19M | -154.68M | -3.0495 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-26 | Iniziato | Deutsche Bank | Buy |
| 2025-04-08 | Iniziato | Leerink Partners | Outperform |
| 2025-03-18 | Iniziato | Wolfe Research | Outperform |
| 2024-09-04 | Iniziato | Wedbush | Outperform |
| 2024-07-16 | Iniziato | Evercore ISI | Outperform |
| 2024-05-02 | Iniziato | Robert W. Baird | Outperform |
| 2024-03-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-12-11 | Iniziato | Guggenheim | Buy |
| 2023-12-11 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2019-03-21 | Iniziato | JP Morgan | Overweight |
| 2018-09-04 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Iniziato | Evercore ISI | Outperform |
| 2018-03-14 | Reiterato | Needham | Buy |
Mostra tutto
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Why Spyre Therapeutics Inc. (3920) stock benefits from AI revolutionWeekly Market Outlook & Weekly Stock Performance Updates - newser.com
Can Spyre Therapeutics Inc. stock deliver strong Q4 earningsMarket Movers & Fast Entry High Yield Tips - newser.com
Is Spyre Therapeutics Inc. (3920) stock worth buying before Fed actionTrend Reversal & Daily Stock Momentum Reports - newser.com
Is Spyre Therapeutics Inc. (3920) stock at risk of policy regulationJuly 2025 Drop Watch & Accurate Intraday Trading Signals - newser.com
Earnings visualization tools for Spyre Therapeutics Inc. - newser.com
Will Spyre Therapeutics Inc. (3920) stock recover faster than industryJuly 2025 Patterns & Fast Entry and Exit Trade Plans - newser.com
Using data tools to time your Spyre Therapeutics Inc. exit2025 Top Gainers & Safe Entry Momentum Tips - newser.com
Why Spyre Therapeutics Inc. stock is seen as undervaluedTrend Reversal & Reliable Entry Point Trade Alerts - newser.com
Backtesting results for Spyre Therapeutics Inc. trading strategiesQuarterly Portfolio Review & Long-Term Safe Investment Plans - newser.com
Will Spyre Therapeutics Inc. (3920) stock see insider accumulationJuly 2025 Recap & Verified Chart Pattern Trade Signals - newser.com
Will Spyre Therapeutics Inc. (3920) stock announce special dividend2025 Earnings Impact & Accurate Intraday Trading Signals - newser.com
Is a relief rally coming for Spyre Therapeutics Inc. holdersQuarterly Investment Review & Free Reliable Trade Execution Plans - newser.com
What margin trends mean for Spyre Therapeutics Inc. stock2025 Geopolitical Influence & Verified Momentum Stock Watchlist - newser.com
Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 - Insider Monkey
Can Spyre Therapeutics Inc. stock sustain free cash flow growth2025 Technical Overview & Free Fast Entry Momentum Trade Alerts - newser.com
Is Spyre Therapeutics Inc. (3920) stock inflation resilientEarnings Trend Report & Weekly Breakout Watchlists - newser.com
Spyre Therapeutics (SYRE): Evaluating Valuation Following Encouraging SPY003 Trial Results and Improved Financials - simplywall.st
Spyre Therapeutics Inc Azioni (SYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):